{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-108864","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.481410+00:00","generated_at":"2026-06-10T00:41:09.949018+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"AbbVie expands board to 13, appoints Jennifer Davis and Susan Quaggin as directors","bullets":["Board expanded from 11 to 13 directors; Jennifer Davis (Class II) and Susan Quaggin (Class III) appointed.","Davis is CEO, Health Care at Procter & Gamble; Quaggin is Irving S. Cutter Professor and Chair of Medicine at Northwestern.","Davis appointed to Nominations and Governance Committee; Quaggin to Public Policy and Sustainability Committee.","Board affirmatively determined both are independent under NYSE standards and AbbVie guidelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-108864","json":"https://secwatch.observer/filing/0001104659-23-108864.json","markdown":"https://secwatch.observer/filing/0001104659-23-108864.md","text":"https://secwatch.observer/filing/0001104659-23-108864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/0001104659-23-108864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/tm2328138d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:41:09.949018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48bb27cc3a","claim":"Jennifer Davis was appointed as Class II director at AbbVie Inc..","evidence_excerpt":"appointed Jennifer Davis as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/0001104659-23-108864-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"bc5f1059a1","claim":"Susan Quaggin was appointed as Class III director at AbbVie Inc..","evidence_excerpt":"and Susan Quaggin as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923108864/0001104659-23-108864-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}